Aastrom Biosciences, Inc. (ASTM) Clinical Trial Application for Phase 2b ixCELL-DCM Study of ixmyelocel-T Approved in Canada
9/16/2013 9:24:36 AM
ANN ARBOR, Mich., Sept. 16, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that Health Canada has approved the company's clinical trial application (CTA) to initiate the ongoing Phase 2b ixCELL-DCM clinical trial in Canada. The ixCELL-DCM study, which is currently enrolling patients in the United States, is a randomized, double-blind, placebo-controlled study of ixmyelocel-T in patients with advanced heart failure due to ischemic dilated cardiomyopathy (DCM).
Help employers find you! Check out all the jobs and post your resume.
comments powered by